Amélie Forest

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text

Medicine, Immunology, Pharmacology +17

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Jean‐Marc Nabholtz, Catherine Abrial, Marie‐Ange Mouret‐Reynier et al. · Annals of Oncology · 2014 · 122 citations

Medicine, Oncology, Pharmacology +17

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

William J. Gradishar, Denise A. Yardley, Rachel M. Layman et al. · Clinical Cancer Research · 2015 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

Atrish Bagchi, Jaafar N. Haidar, Scott W. Eastman et al. · Molecular Cancer Therapeutics · 2017 · 58 citations

Medicine, Oncology, Pharmacology +15

Structure and composition of the postsynaptic density during development

Matthew T. Swulius, Yoshihisa Kubota, Amélie Forest et al. · The Journal of Comparative Neurology · 2010 · 51 citations

Medicine, Neurobiology, Neuroscience +17